Prevalence, types and predictors of potential drug-drug interactions in pulmonology ward of a tertiary care hospital

被引:21
作者
Ismail, Mohammad [1 ]
Iqbal, Zafar [1 ]
Khattak, Muhammad Bilal [2 ]
Javaid, Arshad [3 ]
Khan, Tahir Mehmood [4 ]
机构
[1] Univ Peshawar, Dept Pharm, Peshawar, Kpk, Pakistan
[2] ATH, Abbottabad, Kpk, Pakistan
[3] LRH, PGMI, Peshawar, Kpk, Pakistan
[4] King Faisal Univ, Coll Clin Pharm, Al Hasa, Saudi Arabia
关键词
Drug-drug interactions; potential drug-drug interaction; prescriptions screening; drug related problems; clinical pharmacy; ELDERLY-PATIENTS; ACE-INHIBITORS; HEPATOTOXICITY; RIFAMPIN; THERAPY; SPIRONOLACTONE; PYRAZINAMIDE; TUBERCULOSIS; FUROSEMIDE; MEDICINE;
D O I
10.5897/AJPP11.408
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the study was to identify prevalence, types and predictors of potential drug-drug interactions (pDDIs) in pulmonology ward and to report common interactions. Medical records of 400 randomly-selected patients were reviewed for pDDIs using Micromedex Drug-Reax software. Logistic-regression was applied to determine predictors of pDDIs. We identified 126 interacting-combinations that encountered in total 558 pDDIs with median number of 01 pDDI per patient. Overall 45% patients had at least one pDDI; 24.25% were having at least one major pDDI, and 36% patients had at least one moderate pDDI. Among 558 identified pDDIs, most were of moderate (53.6%) or major severity (34%); good (74.2%) or fair (16.3%) type of scientific-evidence; and delayed onset (70%). Top 15 common pDDIs included 6 major, 7 moderate and 2 minor interactions. There was significant association of the occurrence of pDDIs with patient with age of 60 years or more (p <0.001), hospital stay of 7 days or longer (p = 0.01) and taking 7 or more drugs (p <0.001). We have recorded a high prevalence of pDDIs in pulmonology ward, most of which were of moderate severity. Patients with old age, long hospital stay and increased number of drugs were more exposed to pDDIs.
引用
收藏
页码:1303 / 1309
页数:7
相关论文
共 35 条
[1]  
[Anonymous], 2011, MICROMEDEX DRUG REAX, V148
[2]   BLUNTING OF FUROSEMIDE DIURESIS BY ASPIRIN IN MAN [J].
BARTOLI, E ;
ARRAS, S ;
FAEDDA, R ;
SOGGIA, G ;
SATTA, A ;
OLMEO, NA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 20 (07) :452-458
[3]  
Baxter K., 2010, Stockley's Drug Interactions Pocket Companion 2010
[4]   RIFAMPIN-INDUCED NONRESPONSIVENESS OF GIANT-CELL ARTERITIS TO PREDNISONE TREATMENT [J].
CARRIE, F ;
ROBLOT, P ;
BOUQUET, S ;
DELON, A ;
ROBLOT, F ;
BECQGIRAUDON, B .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (13) :1521-1524
[5]  
Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P735
[6]  
Cruciol-Souza Joice Mara, 2006, Clinics, V61, P515, DOI 10.1590/S1807-59322006000600005
[7]   Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City [J].
Doubova , Svetlana Vladislavovna ;
Reyes-Morales, Hortensia ;
Torres-Arreola, Laura Del Pilar ;
Suarez-Ortega, Magdalena .
BMC HEALTH SERVICES RESEARCH, 2007, 7 (1)
[8]   Potential drug-drug interactions in the medication of medical patients at hospital discharge [J].
Egger, SS ;
Drewe, J ;
Schlienger, RG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (11) :773-778
[9]   Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments [J].
Fokter, Nina ;
Mozina, Martin ;
Brvar, Miran .
WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (3-4) :81-88
[10]   Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy [J].
Gagne, J. J. ;
Maio, V. ;
Rabinowitz, C. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (02) :141-151